VRDN

$28.77+0.00 (+0.00%)

Market OpenAs of Mar 17, 6:54 PM UTC

Viridian Therapeutics, Inc.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$28.77
Potential Upside
5%
Whystock Fair Value$30.21
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclona...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.94B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.01
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-49.16%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
12.37

Recent News

Motley Fool
Mar 15, 2026

VR Adviser Adds Over 1 Million Savara Shares

This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Mar 6, 2026

RBC Capital Lowers Its Price Target on Viridian Therapeutics, Inc. (VRDN) to $42 and Maintains an Outperform Rating

Viridian Therapeutics, Inc. (NASDAQ:VRDN) is among the 10 Fastest Growing NASDAQ Stocks to Buy. On February 27, 2026, RBC Capital lowered its price target on Viridian Therapeutics, Inc. (NASDAQ:VRDN) to $42 from $45 and maintained an Outperform rating. The analyst noted the company reported Q4 EPS and disclosed that veli’ PDUFA is scheduled for June […]

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Feb 27, 2026

What Viridian Therapeutics (VRDN)'s 2025 Losses and Thyroid Eye Disease Milestones Mean For Shareholders

Viridian Therapeutics reported fourth-quarter 2025 revenue of US$132,000 and a net loss of US$120.36 million, while full-year revenue rose to US$70.85 million alongside a net loss of US$342.6 million. The company also highlighted progress for thyroid eye disease programs, including a June 30, 2026 PDUFA date for veligrotug and ongoing Phase 3 trials for elegrobart. We’ll now examine how Viridian’s advancing thyroid eye disease pipeline and detailed 2025 results shape the company’s evolving...

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Feb 26, 2026

Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Misses Revenue Estimates

Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of -20.67% and -99.29%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Feb 26, 2026

MiMedx (MDXG) Q4 Earnings and Revenues Beat Estimates

MiMedx (MDXG) delivered earnings and revenue surprises of +55.56% and +14.93%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.